FDA Nears Decision On Moderna mRNA Flu Shot After February Reversal
The U.S. Food and Drug Administration must decide by Wednesday, August 5, 2026, whether to approve Moderna's experimental mRNA seasonal flu vaccine, a ruling that could reshape mRNA investment and vaccine markets.[1]
An FDA advisory committee recommended the vaccine for approval in June, leaving the agency with the formal Aug. 5 deadline to act.[1] The shot uses the same mRNA technology that public skeptic Robert F. Kennedy Jr. has questioned in recent years.[1]
In February 2026, the FDA sent Moderna a letter refusing to review its application, despite prior discussions indicating the filing could proceed. Roughly a week later, the agency reversed itself after Moderna committed to conduct a confirmatory post-approval study if the vaccine reaches the market.
The Department of Health and Human Services canceled nearly $500 million in mRNA vaccine research funding in summer 2025, and Moderna has delayed some planned mRNA projects while awaiting the flu-shot ruling. Small biotechs and investors say the February refusal and the HHS cuts chilled mRNA investment, making FDA's August decision a bellwether for the field's near-term direction.
Show source details & analysis (1 source)
📌 Key Facts
- In February 2026, FDA sent Moderna a letter refusing to review its application for an mRNA-based flu vaccine, despite prior discussions indicating the filing could proceed.
- Roughly a week later, FDA reversed itself and agreed to review the application after Moderna committed to conduct a confirmatory post-approval study if the vaccine reaches the market.
- An FDA advisory committee recommended approval of the Moderna mRNA flu shot in June 2026, and FDA now has a Wednesday, August 5, 2026 deadline to issue its decision.
- The Department of Health and Human Services canceled nearly $500 million in mRNA vaccine research funding in summer 2025, and Moderna is delaying some planned mRNA projects while awaiting the flu-shot ruling.
- Experts say the combination of FDA’s February refusal and HHS funding cuts has had a chilling effect on mRNA investment, particularly for small biotechs.
📰 Source Timeline (1)
Follow how coverage of this story developed over time